Avalo CMO exercises options and sells 25,492 shares

Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold shares in a linked set of transactions.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle exercised stock options and sold shares in a linked set of transactions. On March 16, 2026, she exercised options to acquire 19,500 shares of common stock at $12.65 per share and 5,992 shares at $8.04 per share.

The same day, she sold 25,492 shares of common stock in open-market transactions at an average price of about $16.1465 per share, in multiple trades between $16.00 and $16.34. Following these transactions, she directly holds 3,622 common shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 25,492 shares ($117K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 25,492 shs ($412K)

Approx. gross sale proceeds $412K

Approx. exercise cost $295K

Approx. pre-tax spread $117K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	19,500	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	5,992	$0.00	$0.00
Exercise	Common Stock	19,500	$12.65	$247K
Exercise	Common Stock	5,992	$8.04	$48K
Sale	Common Stock	25,492	$16.1465	$412K

Holdings After Transaction: Stock Option (Right to Buy) — 363,508 contracts (Direct); Common Stock — 3,622 shares (Direct)

Footnotes (3)

1. F1. The reported securities were sold in multiple transactions at prices ranging from $16.00 to $16.34. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
2. F2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
3. F3. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalo Therapeutics (AVTX) CMO Mittie Doyle report in this Form 4?

Mittie Doyle reported an exercise-and-sell transaction. She exercised stock options to acquire 25,492 Avalo Therapeutics common shares, then sold 25,492 shares in open-market trades, and ended with 3,622 common shares held directly afterward.

How many Avalo Therapeutics (AVTX) shares did Mittie Doyle sell and at what price?

She sold 25,492 Avalo Therapeutics common shares. The sales occurred in multiple open-market transactions at prices between $16.00 and $16.34 per share, with an average price reported as approximately $16.1465 per share for the total block.

What stock options did Mittie Doyle exercise in Avalo Therapeutics (AVTX)?

She exercised options for 19,500 shares with a $12.65 exercise price and 5,992 shares with an $8.04 exercise price. These derivative exercises converted existing stock options into Avalo Therapeutics common shares on March 16, 2026.

How many Avalo Therapeutics (AVTX) shares does Mittie Doyle hold after these transactions?

After completing the option exercises and subsequent share sale, Mittie Doyle directly holds 3,622 shares of Avalo Therapeutics common stock. This figure reflects her reported direct ownership immediately following the March 16, 2026 transactions.

Were Mittie Doyle’s Avalo Therapeutics (AVTX) share sales made in a single trade?

No. The reported Avalo Therapeutics sales were executed in multiple transactions. The filing notes trades occurred at prices ranging from $16.00 to $16.34 per share, and Doyle undertakes to provide detailed trade-level information upon request.

What vesting terms are disclosed for Mittie Doyle’s Avalo Therapeutics (AVTX) stock options?

One option grant vests 25% on July 15, 2025, with the balance vesting monthly over three years. Another vests 25% on January 28, 2026, with the remaining shares also vesting in equal monthly installments over the following three years, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		M		19,500	A	$12.65	23,122	D
Common Stock	03/16/2026		M		5,992	A	$8.04	29,114	D
Common Stock	03/16/2026		S		25,492	D	$16.1465(1)	3,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.65	03/16/2026		M			19,500	(2)	07/15/2034	Common Stock	19,500	$0	214,500	D
Stock Option (Right to Buy)	$8.04	03/16/2026		M			5,992	(3)	01/28/2035	Common Stock	5,992	$0	149,008	D

Explanation of Responses:

1. The reported securities were sold in multiple transactions at prices ranging from $16.00 to $16.34. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

2. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

3. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)